Protective effects of gemigliptin against type II collagen degradation in human chondrocytes - 11/06/18
páginas | 5 |
Iconografías | 8 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Gemigliptin inhibited the degradation of collagen type Ⅱ in human chondrocytes. |
• | Gemigliptin suppressed expression of MMP-1, MMP-3, and MMP-13. |
• | Gemigliptin inhibited the IKK/IκBα/NF-κB pathway and activation of p38. |
Abstract |
Degradation of components of the extracellular matrix such as type II collagen in articular cartilage induced by matrix metalloproteinases (MMPs) has been considered as a major pathological characteristic of osteoarthritis (OA). Gemigliptin is a potent and a highly selective dipeptidyl peptidase-IV (DPP-IV) inhibitor, which has been clinically used as an oral agent for the treatment of type 2 diabetes. However, the effects of gemigliptin on articular cartilage destruction and the pathogenesis of OA remain unknown. In the current study, we addressed for the first time the inhibitory property of gemigliptin against interleukin-1β (IL-1β)-induced degradation of type II collagen in human chondrocytes. Our results demonstrate that gemigliptin treatment inhibited the expression of matrix metalloproteinase 1 (MMP-1), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13) at both the gene and protein levels. Mechanistically, our results indicate that gemigliptin inhibited activation of the nuclear factor-κB (NF-κB) signaling pathway by suppressing phosphorylation of IκB kinase (IKK)/nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor α (IκBα) and p38. Our results implicate that gemigliptin treatment might be a potential therapeutic strategy for chondroprotective therapy.
El texto completo de este artículo está disponible en PDF.Keywords : Gemigliptin, Matrix metalloproteinases, Type II collagen, Osteoarthritis
Esquema
Vol 104
P. 590-594 - août 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?